头孢哌酮配合舒巴坦对于肾盂肾炎的治疗效果及应用安全性探析

Therapeutic effect and application safety of cefoperazone combined with sulbactam for pyelonephritis

目的探究头孢哌酮配合舒巴坦对于肾盂肾炎的治疗效果及应用安全性。方法 84例肾盂肾炎患者,随机分为观察组与对照组,各42例。对照组患者给予左氧氟沙星治疗,观察组患者在对照组基础上开展头孢哌酮配合舒巴坦治疗。比较两组临床疗效、肾功能和血清转化生子因子β1(TFG-β1)水平、不良反应发生率。结果观察组总好转率95.24%高于对照组的73.81%,差异有统计学意义(P<0.05)。治疗后,观察组患者的尿素氮(BUN)(5.79±0.11)mmol/L、血肌酐(Scr)(105.27±2.09)μmol/L、尿微量白蛋白(mALB)(10.68±1.89)mg/L、TFG-β1(101.27±6.83)ng/L均低于对照组的(6.93±0.25)mmol/L、(124.35±4.96)μmol/L、(15.65±2.17)mg/L、(215.64±8.85)ng/L,差异有统计学意义(P<0.05)。观察组不良反应发生率为9.52%,与对照组的4.76%比较,差异无统计学意义(P>0.05)。结论头孢哌酮配合舒巴坦应用于肾盂肾炎临床治疗中的效果可观且安全性较高,具有临床推广价值。

Objective To investigate the therapeutic effect and application safety of cefoperazone combined with sulbactam for pyelonephritis.Methods A total of 84 pyelonephritis patients were randomly divided into observation group and control group,with 42 cases in each group.The control group was treated with levofloxacin,and the observation group was treated with cefoperazone and sulbactam based on the control group.The clinical efficacy,renal function,serum transforming growth factor-β1(TFG-β1)level,and occurrence of adverse reactions were compared between the two groups.Results The total improvement rate 95.24%of the observation group was higher than 73.81%of the control group,and the difference was statistically significant(P<0.05).After treatment,the blood urea nitrogen(BUN)(5.79±0.11)mmol/L,serum creatinine(Scr)(105.27±2.09)μmol/L,urine microalbumin(mALB)(10.68±1.89)mg/L,and TFG-β1(101.27±6.83)ng/L of the observation group were lower than(6.93±0.25)mmol/L,(124.35±4.96)μmol/L,(15.65±2.17)mg/L and(215.64±8.85)ng/L of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 9.52%of the observation group had no statistically significant difference compared with 4.76%of the control group(P>0.05).Conclusion Combination of cefoperazone and sulbactam shows good effect and high safety in clinical treatment of pyelonephritis,and it contains clinical promotion value.